Associated Urological Specialists

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Prostate cancer7 trials
• Bladder cancer5 trials

Phase

• Phase 26 trials
• Phase 32 trials
• Phase 1/21 trial

Status

• Recruiting6 trials
• Active, not recruiting4 trials
• Completed2 trials

Lead sponsor

• Janssen Research & Development, LLC4 trials
• Sumitomo Pharma America, Inc.2 trials
• Astellas Pharma Global Development, Inc.1 trial
• Boston Scientific Corporation1 trial
• CG Oncology, Inc.1 trial
• and 3 more

Running trials

• Recruiting

  A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

  NCT07832292· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

  NCT07309445· Janssen Research & Development, LLC· Source

  Contact: Eliza M. Raymundo, MD, DMCC, FPUA, FPCS

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

  NCT07005154· Phase 2· Astellas Pharma Global Development, Inc.· Source

  Contact: Astellas Pharma Global Development, Inc.

• Active, not recruiting

  An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT06991556· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06995677· Phase 2· Tyra Biosciences, Inc· Source

  Contact: Gina Risdall

• Active, not recruiting

  SpaceIT Hydrogel System for Perirectal Spacing

  NCT06451614· Boston Scientific Corporation· Source

• Recruiting

  Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

  NCT06567743· Phase 2· CG Oncology, Inc.· Source

  Contact: Aaron Berger, MD

• Recruiting

  Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

  NCT06134232· Phase 2· Dendreon· Source

  Contact: Margaret Warner-Lubin

• Active, not recruiting

  Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  NCT05316155· Phase 1/2· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer4 recruiting
• Prostate cancer2 recruiting

Closed trials

• Completed

  Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

  NCT05605964· Phase 3· Sumitomo Pharma America, Inc.· Source

• Completed

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Sumitomo Pharma America, Inc.· Source